Aptevo Therapeutics Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial

Reuters

12/09

Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial

Aptevo Therapeutics Inc. has announced preliminary results from its ongoing Phase 1b/2 RAINIER clinical study evaluating mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. The data, presented on December 8, 2025, at the American Society of Hematology $(ASH)$ Annual Meeting, showed that across dose-optimization cohorts 1-3, 100% of patients remained free of cytokine release syndrome. The overall response rate among evaluable patients was 93%, with 87% achieving complete remission or complete remission with incomplete hematologic recovery, and 73% achieving complete remission. Additionally, 60% of MRD-evaluable patients who achieved remission were negative for minimal residual disease. The study is ongoing, with continued patient enrollment at additional dose levels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115772) on December 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2590349514"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590349514\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590349514?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590349514","market":"fut","top_or_hot":-1,"title":"Aptevo Therapeutics Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> has announced preliminary results from its ongoing Phase 1b/2 RAINIER clinical study evaluating mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. The data, presented on December 8, 2025, at the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, showed that across dose-optimization cohorts 1-3, 100% of patients remained free of cytokine release syndrome. The overall response rate among evaluable patients was 93%, with 87% achieving complete remission or complete remission with incomplete hematologic recovery, and 73% achieving complete remission. Additionally, 60% of MRD-evaluable patients who achieved remission were negative for minimal residual disease. The study is ongoing, with continued patient enrollment at additional dose levels.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115772) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> has announced preliminary results from its ongoing Phase 1b/2 RAINIER clinical study evaluating mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. The data, presented on December 8, 2025, at the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, showed that across dose-optimization cohorts 1-3, 100% of patients remained free of cytokine release syndrome. The overall response rate among evaluable patients was 93%, with 87% achieving complete remission or complete remission with incomplete hematologic recovery, and 73% achieving complete remission. Additionally, 60% of MRD-evaluable patients who achieved remission were negative for minimal residual disease. The study is ongoing, with continued patient enrollment at additional dose levels.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115772) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL4HxSrD:1","article_id":"2590349514","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590349514","pubTimestamp":1765285520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptevo Therapeutics Inc. has announced preliminary results from its ongoing Phase 1b/2 RAINIER clinical study evaluating mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia  patients unfit for intensive chemotherapy. The data, presented on December 8, 2025, at the American Society of Hematology  Annual Meeting, showed that across dose-optimization cohorts 1-3, 100% of patients remained free of cytokine release syndrome. The overall response rate among evaluable patients was 93%, with 87% achieving complete remission or complete remission with incomplete hematologic recovery, and 73% achieving complete remission. Additionally, 60% of MRD-evaluable patients who achieved remission were negative for minimal residual disease. The study is ongoing, with continued patient enrollment at additional dose levels.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APVO":"Aptevo Therapeutics Inc."},"translate_title":"Aptevo Therapeutics报告Mipletamig在一线AML试验中具有强劲的缓解率和安全性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":0.9},"content_text":"Aptevo Therapeutics Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial\n    \n\nAptevo Therapeutics Inc. has announced preliminary results from its ongoing Phase 1b/2 RAINIER clinical study evaluating mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax for newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. The data, presented on December 8, 2025, at the American Society of Hematology $(ASH)$ Annual Meeting, showed that across dose-optimization cohorts 1-3, 100% of patients remained free of cytokine release syndrome. The overall response rate among evaluable patients was 93%, with 87% achieving complete remission or complete remission with incomplete hematologic recovery, and 73% achieving complete remission. Additionally, 60% of MRD-evaluable patients who achieved remission were negative for minimal residual disease. The study is ongoing, with continued patient enrollment at additional dose levels.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115772) on December 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}